Phio Pharmaceuticals And 2 Other Stocks Under $2 Insiders Are Buying

6/12/24 7:07:08 AM ET

Diversified Commercial Services

Consumer Discretionary

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $FPAY alert in real time by email

The Dow Jones index closed lower by more than 100 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

CarParts.com

The Trade: CarParts.com, Inc. (NASDAQ:PRTS) Director Jim Barnes bought a total of 94,000 shares at an average price of $1.10. To acquire these shares, it cost around $103,400.
What's Happening: On May 7, CarParts.com posted downbeat quarterly results.
What CarParts.com Does: CarParts.com Inc is an online provider of automotive aftermarket parts and repair information.

Phio Pharmaceuticals

The Trade: Phio Pharmaceuticals Corp. (NASDAQ:PHIO) President and CEO Robert J Bitterman acquired a total of 1,000 shares at an average price of $0.74. To acquire these shares, it cost around $740.
What's Happening: On May 17, Phio Pharmaceuticals files for mixed shelf of upto $100 million.
What Phio Pharmaceuticals Does: Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells.

FlexShopper

Check This Out: Top 4 Health Care Stocks That May Keep You Up At Night This Month

Get the next $FPAY alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$FPAY
$PHIO
$PRTS

Company	Date	Price Target	Rating	Analyst
Phio Pharmaceuticals Corp. $PHIO	6/5/2025	$14.00	Buy	H.C. Wainwright
CarParts.com Inc. $PRTS	3/6/2025	$3.00	Hold → Buy	Craig Hallum
CarParts.com Inc. $PRTS	3/4/2022	$18.00	Buy	Lake Street
CarParts.com Inc. $PRTS	12/28/2021	$30.00 → $18.00	Buy	Roth Capital
CarParts.com Inc. $PRTS	8/6/2021	$18.00 → $21.00	Outperform	RBC Capital

More analyst ratings

$FPAY
$PHIO
$PRTS
Press Releases

Fastest customizable press release news feed in the world

Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894

Leadership Enhancements Position Company for Upcoming Regulatory Engagement and Clinical MilestonesNew Appointments Reinforce Operational Readiness Across Finance, Regulatory Affairs and Program LeadershipKing of Prussia, Pennsylvania--(Newsfile Corp. - February 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals Corp. today announced leadership appointments as the Company prepares for upcoming regulatory discussions and key clinical milestones for PH-762, while continuing work on PH-894.The Company promoted Lisa Carso

2/19/26 7:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

CarParts.com Sets Fourth Quarter 2025 Conference Call for Thursday, March 5, 2026

LOS ANGELES, Feb. 12, 2026 /PRNewswire/ -- CarParts.com, Inc. (NASDAQ:PRTS) will hold a conference call on Thursday, March 5, 2026 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss its financial results for the fourth quarter and fiscal year ended January 3, 2026. The results will be reported in a press release prior to the call. CarParts.com, Inc. CEO David Meniane and Interim CFO Mark DiSiena will host the conference call live via an audio webcast. The live webcast of the event can be accessed at www.carparts.com/investor/news-events. A replay of the webcast will

2/12/26 4:01:00 PM ET

Auto & Home Supply Stores

Consumer Discretionary

Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial

Maximum Dose Concentration in Final Cohort Yields 85% Pathological Response (6 of 7 Patients); Complete Response (100% Tumor Clearance) in 4 of 6 RespondersNo Serious Adverse Events or Dose-Limiting Toxicities Identified Across All 5 Dose Escalation CohortsKing of Prussia, Pennsylvania--(Newsfile Corp. - February 10, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that the Safety Monitoring Committee (SMC) has concluded its planned safety review for all patients treated with the INTASYL compound PH-762 in Phio's Phase

2/10/26 7:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

$FPAY
$PHIO
$PRTS
Leadership Updates

Live Leadership Updates

Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference

Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ.Robert Bitterman, CEO and Chairman of the Board of Phio Pharmaceuticals will deliver a company presentation on January 28th at 9 AM in Borgata Hotel Room #1 and the management team will be avai

1/26/26 8:15:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

King of Prussia, Pennsylvania--(Newsfile Corp. - October 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that David Deming has been appointed Lead Independent Director of the Board of Directors of Phio Pharmaceuticals. Mr. Deming brings over 30 years of experience in investment banking and asset management to his new role as Lead Independent Director. He was with JP Morgan for over 27 years, both in M&A and leading the Health Group in investment banking for his last 12 years there. Mr. Deming was appointed

10/31/25 10:15:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Registration Link Below for October 28, 2025 12 PM EST Presentation and Live Q&AKing of Prussia, Pennsylvania--(Newsfile Corp. - October 21, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Recently, positive interim safety and efficacy results were reported in the o

10/21/25 7:45:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

$FPAY
$PHIO
$PRTS
Financials

Live finance-specific insights

CarParts.com Sets Fourth Quarter 2025 Conference Call for Thursday, March 5, 2026

LOS ANGELES, Feb. 12, 2026 /PRNewswire/ -- CarParts.com, Inc. (NASDAQ:PRTS) will hold a conference call on Thursday, March 5, 2026 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss its financial results for the fourth quarter and fiscal year ended January 3, 2026. The results will be reported in a press release prior to the call. CarParts.com, Inc. CEO David Meniane and Interim CFO Mark DiSiena will host the conference call live via an audio webcast. The live webcast of the event can be accessed at www.carparts.com/investor/news-events. A replay of the webcast will

2/12/26 4:01:00 PM ET

Auto & Home Supply Stores

Consumer Discretionary

CarParts.com Reports Third Quarter 2025 Results

TORRANCE, Calif., Nov. 10, 2025 /PRNewswire/ -- CarParts.com, Inc. (NASDAQ:PRTS), a leading eCommerce provider of automotive parts and accessories, and a premier destination for vehicle repair and maintenance needs, is reporting results for the third quarter ended September 27, 2025. Third Quarter 2025 Summary vs. Year-Ago Quarter Net sales decreased 12% to $127.8 million.Gross profit of $42.3 million vs. $51.0 million, with gross margin of 33.1%.Net loss was ($10.9) million, or ($0.19) per share, compared to a net loss of ($10.0) million, or ($0.17) per share.Adjusted EBITDA

11/10/25 4:01:00 PM ET

Auto & Home Supply Stores

Consumer Discretionary

CarParts.com Announces Date Change for its Third Quarter 2025 Conference Call

LOS ANGELES, Oct. 31, 2025 /PRNewswire/ -- CarParts.com, Inc. (NASDAQ:PRTS) today announced that the company has rescheduled the date of its third quarter 2025 conference call. The company will now have the call on Monday, November 10, 2025 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). The results will be reported in a press release prior to the call. CarParts.com, Inc. CEO David Meniane and CFO Ryan Lockwood will host the conference call live via an audio webcast. The live webcast of the event can be accessed at www.carparts.com/investor/news-events. A replay of the web

10/31/25 4:01:00 PM ET

Auto & Home Supply Stores

Consumer Discretionary